These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11220298)

  • 1. Anticipated US approval for rosiglitazone and pioglitazone.
    Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
    Gorman C
    Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone approved for treatment of type 2 diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
    [No Abstract]   [Full Text] [Related]  

  • 6. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warner Lambert/Sankyo diabetes drug nears market.
    Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
    [No Abstract]   [Full Text] [Related]  

  • 8. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 9. [First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
    MMW Fortschr Med; 2000 Sep; 142(36):50. PubMed ID: 11021073
    [No Abstract]   [Full Text] [Related]  

  • 10. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
    Lotz N
    MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
    [No Abstract]   [Full Text] [Related]  

  • 11. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
    Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone: failure of oversight or demons imagined?
    Susman J
    J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
    [No Abstract]   [Full Text] [Related]  

  • 13. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosiglitazone monotherapy and type 2 diabetes.
    Lawrence IG
    Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approves pioglitazone for diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 18. Pioglitazone: the future.
    Brunetti P
    Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone: a case of regulatory hubris.
    Nissen SE
    BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
    [No Abstract]   [Full Text] [Related]  

  • 20. Pioglitazone (Actos).
    Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.